Mammalian Cell Fermentation Technology Market Report: Trends, Forecast and Competitive Analysis to 2030

Mammalian Cell Fermentation Technology Trends and Forecast

The future of the global mammalian cell fermentation technology market looks promising with opportunities in the monoclonal antibody, recombinant protein, vaccine, hormone, and enzyme markets. The global mammalian cell fermentation technology market is expected to reach an estimated $56.5 billion by 2030 with a CAGR of 7.3% from 2024 to 2030. The major drivers for this market are rising rates of chronic illness, expanding need for personalized medications, and increasing need for biosimilars and biologics.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Mammalian Cell Fermentation Technology by Segment

The study includes a forecast for the global mammalian cell fermentation technology by type, application, end use, and region.

Mammalian Cell Fermentation Technology Market by Type [Shipment Analysis by Value from 2018 to 2030]:

• Chinese Hamster Ovary Cell Fermentation
• Human Embryonic Kidney Cell Fermentation
• Baby Hamster Kidney Cell Fermentation
• Murine Myeloma Cell Fermentation
• Others

Mammalian Cell Fermentation Technology Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Hormones
• Enzymes
• Others

Mammalian Cell Fermentation Technology Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Biopharmaceutical Companies
• CMOs & CDMOs
• Academic & Research Institutes

Mammalian Cell Fermentation Technology Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Mammalian Cell Fermentation Technology Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mammalian cell fermentation technology companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mammalian cell fermentation technology companies profiled in this report include-

• Thermo Fisher Scientific
• Merck
• Danaher
• Lonza
• F. Hoffmann-La Roche
• Sartorius
• AstraZeneca
• Bristol-Myers Squibb
• Amgen
• Gilead Sciences

Mammalian Cell Fermentation Technology Market Insights

Lucintel forecasts that Chinese hamster ovary will remain the largest segment over the forecast period due to their ability to produce sizable amounts of recombinant proteins and their clearly defined genetic and biochemical properties.

Within this market, monoclonal antibody will remain the largest segment due to substantial usage of mammalian cell fermentation in this application given to its capacity to produce large amounts of high-quality proteins with strong biological activity in an efficient manner.

North America will remain the largest region over the forecast period due to availability of well-developed healthcare system and existence of key biopharmaceutical companies in the region.

Features of the Global Mammalian Cell Fermentation Technology Market

Market Size Estimates: Mammalian cell fermentation technology market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Mammalian cell fermentation technology market size by type, application, end use, and region in terms of value ($B).

Regional Analysis: Mammalian cell fermentation technology market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the mammalian cell fermentation technology market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mammalian cell fermentation technology market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the mammalian cell fermentation technology market size?

Answer: The global mammalian cell fermentation technology market is expected to reach an estimated $56.5 billion by 2030.

Q2. What is the growth forecast for mammalian cell fermentation technology market?

Answer: The global mammalian cell fermentation technology market is expected to grow with a CAGR of 7.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the mammalian cell fermentation technology market?

Answer: The major drivers for this market are rising rates of chronic illness, expanding need for personalized medications, and increasing need for biosimilars and biologics.

Q4. What are the major segments for mammalian cell fermentation technology market?

Answer: The future of the mammalian cell fermentation technology market looks promising with opportunities in the monoclonal antibody, recombinant protein, vaccine, hormone, and enzyme markets.

Q5. Who are the key mammalian cell fermentation technology market companies?

Answer: Some of the key mammalian cell fermentation technology companies are as follows:

• Thermo Fisher Scientific
• Merck
• Danaher
• Lonza
• F. Hoffmann-La Roche
• Sartorius
• AstraZeneca
• Bristol-Myers Squibb
• Amgen
• Gilead Sciences

Q6. Which mammalian cell fermentation technology market segment will be the largest in future?

Answer: Lucintel forecasts that Chinese hamster ovary will remain the largest segment over the forecast period due to their ability to produce sizable amounts of recombinant proteins and their clearly defined genetic and biochemical properties.

Q7. In mammalian cell fermentation technology market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to availability of well-developed healthcare system and existence of key biopharmaceutical companies in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the mammalian cell fermentation technology market by type (Chinese hamster ovary cell fermentation, human embryonic kidney cell fermentation, baby hamster kidney cell fermentation, murine myeloma cell fermentation, and others), application (monoclonal antibodies, recombinant proteins, vaccines, hormones, enzymes, and others), end use (biopharmaceutical companies, CMOs & CDMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?